Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Oncology

CTCL vs. CBCL: Knowing Your Specific Subtype

At a Glance

Primary cutaneous lymphomas are classified into T-cell (CTCL) and B-cell (CBCL) subtypes, which determine if the disease is slow-growing (indolent) or fast-moving (aggressive). Knowing your exact subtype is crucial because it dictates your entire treatment plan.

While all primary cutaneous lymphomas (PCL) begin in the immune system’s white blood cells, they are not all the same. The most critical piece of information your care team needs is your specific subtype. This classification determines whether your disease is slow-growing (indolent) or fast-moving (aggressive), and it dictates every step of your treatment plan [1][2].

The Biological Engine: T-Cells vs. B-Cells

Lymphoma occurs when white blood cells (lymphocytes) undergo acquired “genetic changes” (mutations that develop during your lifetime, not ones that you inherited or can pass to your children) that tell them to multiply and “home” specifically to your skin [3]. There are two main engines that drive this:

  • T-Cells (CTCL): These cells are the “generals” of your immune system. Cutaneous T-Cell Lymphoma is the most common form, accounting for about 75% to 80% of all skin lymphomas [1][4].
  • B-Cells (CBCL): These cells normally produce antibodies to fight infection. Cutaneous B-Cell Lymphoma is less common, making up the remaining 20% to 25% of cases [1].

Subtype Matrix: Understanding Behavior

The 2022 World Health Organization (WHO) update has refined how we name and treat these diseases. The goal of the new classification is to ensure that very slow-growing conditions are not over-treated [5].

Subtype Group Common Names Behavior Key Features
CTCL (T-Cell) Mycosis Fungoides (MF) Indolent The most common subtype. Typically moves slowly from patches to plaques over decades [6].
CTCL (T-Cell) Sézary Syndrome (SS) Aggressive A rare, leukemic form where cancer cells are in the blood; causes total body redness (erythroderma) [7].
CBCL (B-Cell) Marginal Zone (PCMZL) Indolent Extremely slow-growing. Often appears as red-to-purple bumps on the trunk or arms [8].
CBCL (B-Cell) Follicle Center (PCFCL) Indolent The most common B-cell type. Usually presents as firm, painless red nodules on the head or neck [2].
CBCL (B-Cell) Leg Type (PCDLBCL-LT) Aggressive Most often occurs on the lower legs of older adults. Requires faster, more intensive treatment [9].

Important 2022 Updates

The medical community has recently shifted the language for certain subtypes to be more accurate. For example, CD4+ small/medium-sized T-cell lymphoproliferative disorder was formerly called a “lymphoma,” but it is now classified as a “disorder” because it is so slow-growing that it rarely requires aggressive therapy [5][10].

Why Subtype Matters

Knowing your subtype is the difference between a “wait and see” approach and a recommendation for systemic treatment.

  • Indolent Subtypes (MF, PCMZL, PCFCL) are often managed like chronic skin conditions—using creams or light therapy—with the goal of maintaining a high quality of life [11].
  • Aggressive Subtypes (Sézary Syndrome, Leg Type) are treated more like traditional internal lymphomas, often requiring medications that work throughout the entire body (systemic therapy) to get the disease under control quickly [9][12].

Return to Home

Common questions in this guide

What is the difference between CTCL and CBCL?
CTCL (Cutaneous T-Cell Lymphoma) begins in T-cells and makes up about 75% to 80% of skin lymphomas. CBCL (Cutaneous B-Cell Lymphoma) starts in B-cells and accounts for the remaining 20% to 25% of cases.
Is primary cutaneous lymphoma aggressive or slow-growing?
It depends on your specific subtype. Some subtypes like Mycosis Fungoides are indolent, meaning they are very slow-growing. Others, like Sézary Syndrome or Leg Type CBCL, are aggressive and require faster, systemic treatment.
Why was my skin lymphoma reclassified as a lymphoproliferative disorder?
The 2022 World Health Organization update changed the name of certain very slow-growing conditions to 'disorders' rather than 'lymphomas.' This helps ensure these slow-moving conditions are managed appropriately and not over-treated.
How are indolent cutaneous lymphomas treated compared to aggressive types?
Indolent subtypes are often managed like chronic skin conditions using creams or light therapy to maintain quality of life. Aggressive subtypes require systemic therapies that work throughout the entire body to control the disease.
What is Mycosis Fungoides?
Mycosis Fungoides is the most common subtype of Cutaneous T-Cell Lymphoma. It is an indolent condition that typically progresses very slowly from patches to plaques on the skin over several decades.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report confirm if I have a T-cell or a B-cell lymphoma?
  2. 2.Based on the 2022 WHO classification, is my diagnosis considered a 'lymphoma' or a 'lymphoproliferative disorder'?
  3. 3.Is my specific subtype considered indolent or aggressive, and how does that change our treatment approach?
  4. 4.If I have Mycosis Fungoides, which variant do I have (Classic, Folliculotropic, etc.)?
  5. 5.For my B-cell diagnosis, was testing for BCL2 or MYC expression performed?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.

    Hristov AC, Tejasvi T, Wilcox RA

    American journal of hematology 2023; (98(8)):1326-1332 doi:10.1002/ajh.26968.

    PMID: 37434388
  2. 2

    An unusual case of B-cell lymphoma of the scalp.

    Chaudhry N, Qureshi A, Gollamudi S, et al.

    Journal of surgical case reports 2023; (2023(11)):rjad639 doi:10.1093/jscr/rjad639.

    PMID: 38045789
  3. 3

    Cutaneous T-Cell Lymphoma and Microbiota: Etiopathogenesis and Potential New Therapeutic Targets.

    Rodríguez Baeza D, Bejarano Antonio L, González de Arriba M, et al.

    Dermatology research and practice 2024; (2024()):9919225 doi:10.1155/2024/9919225.

    PMID: 38435536
  4. 4

    Relative Frequency, Clinical Features, and Survival Outcomes of 395 Patients with Cutaneous Lymphoma in Korea: A Subgroup Analysis per 10-year Period.

    Lee WJ, Lee SH, Moon IJ, et al.

    Acta dermato-venereologica 2016; (96(7)):888-893 doi:10.2340/00015555-2404.

    PMID: 26975334
  5. 5

    Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoproliferative disorder: Report of a case and review of the literature.

    Keeling BH, Gavino ACP, Admirand J, Soldano AC

    Journal of cutaneous pathology 2017; (44(11)):944-947 doi:10.1111/cup.13011.

    PMID: 28749588
  6. 6

    Mycosis fungoides: a review.

    Sheern C, Levell NJ, Craig PJ, et al.

    Clinical and experimental dermatology 2025; (50(12)):2365-2375 doi:10.1093/ced/llaf341.

    PMID: 40721285
  7. 7

    The Treatment of Advanced-Stage Mycosis Fungoides and Sezary Syndrome: a Hematologist's Point of View.

    Giordano A, Pagano L

    Mediterranean journal of hematology and infectious diseases 2022; (14(1)):e2022029 doi:10.4084/MJHID.2022.029.

    PMID: 35444765
  8. 8

    A nose for trouble: Marginal zone lymphoma masquerading as cutaneous lupus erythematosus.

    Mangkorntongsakul V, Charlton OA, Phan K, et al.

    Dermatologic therapy 2020; (33(6)):e14409 doi:10.1111/dth.14409.

    PMID: 33090618
  9. 9

    A case of a primary cutaneous diffuse large B-cell lymphoma, leg type.

    Marasca C, Fabbrocini G, Cinelli E, et al.

    International wound journal 2020; (17(2)):514-515 doi:10.1111/iwj.13298.

    PMID: 31884690
  10. 10

    Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma.

    Alberti-Violetti S, Torres-Cabala CA, Talpur R, et al.

    Journal of cutaneous pathology 2016; (43(12)):1121-1130 doi:10.1111/cup.12806.

    PMID: 27550169
  11. 11

    Management Strategies for Mycosis Fungoides in India.

    Raychaudhury T

    Indian journal of dermatology 2017; (62(2)):137-141 doi:10.4103/ijd.IJD_71_17.

    PMID: 28400632
  12. 12

    Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy.

    Marrero-Alemán G, Montenegro-Dámaso T, Peñate Y

    The American Journal of dermatopathology 2017; (39(10)):785-787 doi:10.1097/DAD.0000000000000874.

    PMID: 28926365

This page explains primary cutaneous lymphoma subtypes for educational purposes. Your oncologist or dermatologist is the best source for interpreting your specific diagnosis and determining your treatment plan.

Get notified when new evidence is published on Primary cutaneous lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.